{"id":379120,"date":"2020-11-11T17:33:15","date_gmt":"2020-11-11T22:33:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379120"},"modified":"2020-11-11T17:33:15","modified_gmt":"2020-11-11T22:33:15","slug":"ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/","title":{"rendered":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20"},"content":{"rendered":"
\n

\n
\n \u2013 <\/em>
\n <\/strong>
\n
\n Event <\/em>
\n <\/strong>
\n
\n will provide an overview <\/em>
\n <\/strong>
\n
\n of how <\/em>
\n <\/strong>
\n
\n A<\/em>
\n <\/strong>
\n
\n s<\/em>
\n <\/strong>
\n
\n cendis <\/em>
\n <\/strong>
\n
\n is applying <\/em>
\n <\/strong>
\n
\n its<\/em>
\n <\/strong>
\n
\n TransCon<\/em>
\n <\/strong>\u2122 technology <\/em><\/strong>platform <\/em><\/strong>and <\/em><\/strong>its<\/em><\/strong>unique algorithm for product innovation to <\/em><\/strong>the therapeutic area of <\/em><\/strong>o<\/em><\/strong>ncology<\/em><\/strong>\u2013<\/em><\/strong><\/p>\n

COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020.<\/p>\n

The event will provide an overview on the company\u2019s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent a paradigm shift in treating patients with cancer.<\/p>\n

The event will include updates on Ascendis\u2019 two leading oncology programs: TransCon TLR7\/8 Agonist and TransCon IL-2 \u03b2\/\u03b3, for long-lasting activation of Toll-like receptor (TLR)7\/8 or interleukin-2 ( IL-2) receptor \u03b2\/\u03b3, respectively.<\/p>\n

\n Oncology <\/strong>
\n R&D <\/strong>
\n Day <\/strong>
\n Conference Call and Webcast information<\/strong>\n <\/p>\n

Ascendis Pharma will host a conference call and webcast on Friday, November 20, 2020 at 12:00 p.m. Eastern Time (ET) to provide an overview and update the company\u2019s oncology product pipeline. Details include:<\/p>\n\n\n\n\n\n\n
\n Date<\/strong>\n <\/td>\nNovember 20, 2020<\/td>\n<\/tr>\n
\n Time<\/strong>\n <\/td>\n12:00 p.m. to 1:30 p.m. ET<\/td>\n<\/tr>\n
\n Dial In (U.S.)<\/strong>\n <\/td>\n844-290-3904<\/td>\n<\/tr>\n
\n Dial In (International)<\/strong>\n <\/td>\n574-990-1036<\/td>\n<\/tr>\n
\n Access Code<\/strong>\n <\/td>\n8695366<\/td>\n<\/tr>\n<\/table>\n

A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com<\/u><\/a>. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.<\/p>\n

\n About\u00a0Ascendis Pharma A\/S\u00a0<\/strong>\n <\/p>\n

Ascendis Pharma\u00a0is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients\u2019 lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.<\/p>\n

Ascendis Pharma\u00a0currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in\u00a0Copenhagen, Denmark, with additional offices in Heidelberg and\u00a0Berlin, Germany, and in\u00a0Palo Alto\u00a0and\u00a0Redwood City, California.<\/p>\n

For more information, please visit www.ascendispharma.com<\/strong><\/a>.<\/strong><\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 strategy to create product opportunities that have the potential to represent a completely new paradigm shift in treating patients with cancer, (ii) Ascendis\u2019 ability to apply its platform technology to build a leading, fully integrated biopharmaceutical company, (iii) Ascendis\u2019 product pipeline and expansion into additional therapeutic areas and (iv) Ascendis\u2019 expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities and the effects on its business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 prospectus supplement filed on\u00a0July 9, 2020\u00a0and Ascendis\u2019 current and future reports filed with, or submitted to, the\u00a0U.S. Securities and Exchange Commission\u00a0(SEC), including its Annual Report on Form 20-F filed with the\u00a0SEC\u00a0on\u00a0April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n

\n Ascendis,\u00a0Ascendis Pharma, the\u00a0Ascendis Pharma\u00a0logo, the company logo and TransCon are trademarks owned by the\u00a0Ascendis Pharma Group. \u00a9\u00a0November 2020\u00a0Ascendis Pharma A\/S.<\/em>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n Investor contacts:<\/strong>
\n <\/u>\n <\/td>\n		\n
\n Media contact:<\/strong>
\n <\/u>\n <\/td>\n<\/tr>\n
Tim Lee<\/td>\nRon Rogers<\/td>\n<\/tr>\n
Ascendis Pharma<\/td>\nAscendis Pharma<\/td>\n<\/tr>\n
(650) 374-6343<\/td>\n(650) 507-5208<\/td>\n<\/tr>\n
\n tle@ascendispharma.com<\/a>\n <\/td>\n\n rrs@ascendispharma.com<\/a>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Patti Bank<\/td>\n\u00a0<\/td>\n<\/tr>\n
Westwicke Partners<\/td>\n\u00a0<\/td>\n<\/tr>\n
(415) 513-1284<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n patti.bank@westwicke.com<\/a>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n ir@ascendispharma.com<\/a>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Event will provide an overview of how A s cendis is applying its TransCon \u2122 technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology\u2013 COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020. The event will provide an overview on the company\u2019s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent … <\/p>\n

Continue reading “Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379120","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAscendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Event will provide an overview of how A s cendis is applying its TransCon \u2122 technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology\u2013 COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020. The event will provide an overview on the company\u2019s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent … Continue reading "Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-11T22:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascendis Pharma A\\\/S to Host Virtual Oncology R&D Day on Friday, November 20\",\"datePublished\":\"2020-11-11T22:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/\"},\"wordCount\":897,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/\",\"name\":\"Ascendis Pharma A\\\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=\",\"datePublished\":\"2020-11-11T22:33:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma A\\\/S to Host Virtual Oncology R&D Day on Friday, November 20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk","og_description":"\u2013 Event will provide an overview of how A s cendis is applying its TransCon \u2122 technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology\u2013 COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020. The event will provide an overview on the company\u2019s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent … Continue reading \"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-11T22:33:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20","datePublished":"2020-11-11T22:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/"},"wordCount":897,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/","name":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=","datePublished":"2020-11-11T22:33:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ1NyMzODIyODMwIzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma A\/S to Host Virtual Oncology R&D Day on Friday, November 20"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379120"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379120\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}